DrugPatentWatch Database Preview

Pharmacyclics Inc Company Profile

PHARMACYCLICS INC has two approved drugs.

There are twenty-nine US patents protecting PHARMACYCLICS INC drugs.

There are two hundred and thirty-one patent family members on PHARMACYCLICS INC drugs in thirty-nine countries and twenty-five supplementary protection certificates in eleven countries.

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-002	Feb 16, 2018		RX	Yes	No	8,497,277	➤ Sign Up				➤ Sign Up
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-002	Feb 16, 2018		RX	Yes	No	9,814,721	➤ Sign Up				➤ Sign Up
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No	8,952,015	➤ Sign Up				➤ Sign Up
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes	8,476,284	➤ Sign Up				➤ Sign Up
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	No	8,952,015	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	70 mg	➤ Subscribe	2018-12-14
➤ Subscribe	Tablets	280 mg and 420 mg	➤ Subscribe	2018-12-14
➤ Subscribe	Tablets	140 mg and 560 mg	➤ Subscribe	2018-11-05

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration
Uruguay	34848	➤ Sign Up
Slovenia	2526933	➤ Sign Up
Eurasian Patent Organization	201000599	➤ Sign Up
Slovenia	2529622	➤ Sign Up
Australia	2010201052	➤ Sign Up
Country	Patent Number	Estimated Expiration

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2201840	PA2015017,C2201840	Lithuania	➤ Sign Up	PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021
2201840	300728	Netherlands	➤ Sign Up	DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
2201840	15C0029	France	➤ Sign Up	PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2526934	PA2016034	Lithuania	➤ Sign Up	PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526
2529621	PA2017009	Lithuania	➤ Sign Up	PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.